Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Coadministration of rilpivirine, emtricitabine/rilpivirine/tenofovir DF, or emtricitabine/rilpivirine/tenofovir AF and H2RAs should be undertaken with caution as rilpivirine plasma concentrations may be significantly decreased[FDA Rilpivirine; FDA Emtricitabine/Rilpivirine/Tenofovir; FDA Emtricitabine/Rilpivirine/TAF]
- Rilpivirine, emtricitabine/rilpivirine/tenofovir DF, or emtricitabine/rilpivirine/tenofovir AF are strictly contraindicated with PPIs due to significant decreases in rilpivirine plasma concentrations[FDA Rilpivirine; FDA Emtricitabine/Rilpivirine/Tenofovir; FDA Emtricitabine/Rilpivirine/TAF]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pharmacokinetics